Navigation Links
Empi's Hybresis Solves 'Pain Points' for Physical Therapists
Date:1/21/2008

PTs Report Wireless Hybrid Iontophoresis System Delivers Precise Dose Control, Reduces Patient Discomfort and Shortens In-Clinic Treatment Times

ST. PAUL, Minn., Jan. 21 /PRNewswire/ -- For years, physical therapists have relied on iontophoresis as a safe, reliable and effective drug delivery method. At the same time, most PTs have suffered the drawbacks of traditional dose controllers, lead wires and patch-only iontophoresis systems. This traditional system also includes extensive wear times, patient patch sensitivity and imprecise dosage delivery, which can all lead to unpredictable results. The industry's first wireless hybrid iontophoresis system, Hybresis, is a convenient, needle-free drug delivery system that allows clinicians to treat more patients while improving overall care by reducing patient discomfort and inconvenience.

According to the National Institute of Health (NIH), more than 50 million Americans annually suffer from chronic pain. Traditional pain management treatments include needle injections of anti-inflammatory drugs, narcotics, time-consuming in-clinic treatments or surgery -- all of which often result in unnecessary pain, side effects, anxiety or inconvenience for patients. Hybresis significantly reduces the total in-clinic time, enabling PTs to help move more patients through the clinic faster. Ultimately, PTs can spend more time on providing care.

PTs, including Rick Mewes, OCS, who works in a sports medicine clinic in Minneapolis, have reported that the Hybresis system offers the power of the traditional dose controllers and lead wires, with the flexibility of a patch. "With Hybresis, my patients can be treated effectively in less than half the time it takes for traditional iontophoresis," said Mewes. "My patients have also responded favorably -- opting for the convenience that Hybresis offers over other methods. The greatest benefit I've seen from using Hybresis is that I can now spend more time providing therapy, rather than wasting the time that's required for other iontophoresis treatments to be administered."

The Hybresis system consists of a charging station with four controller bays, a wireless, rechargeable controller and an iontophoresis patch. The patches have an internal battery, which powers the delivery of the medicine during and upon removal of the external Hybresis device. The Hybresis Dose Controller connects to the patch and powers a three-minute initial treatment, allowing for increased absorption that leads to more controlled therapy. After three minutes, the Dose Controller is removed and the Patch is powered to deliver the remainder of the therapy to the patient -- providing patients with the mobility to leave the clinic. After approximately one to two hours, the treatment is complete and patients should remove and discard the patch.

Hybresis patient benefits include:

-- Significantly shorter in-clinic and overall wear times

-- A more discreet and comfortable system which reduces the likelihood of

skin irritation

-- A gentle, hypoallergenic patch adhesive and ergonomic design that

conforms to the treatment area

-- Virtually painless treatment without anti-inflammatory injections,

thereby reducing the risk of infection and minimizing potential for

tissue trauma from the needle

"My pain used to prevent me from doing everyday activities like lifting weights, exercising and using some hand tools on do-it-yourself projects," said patient Bob Gubrud, who recently suffered a shoulder injury due to a bike accident. "Since my PT offered Hybresis, the road to recovery has been much faster. I was in and out of the clinic quickly and able to get back to doing my everyday activities feeling pain-free."

"With a continued rise in the aging population and the number of people suffering from chronic pain, America today is facing a pain epidemic. Now more than ever, healthcare professionals need the right tools to treat their patients, who often have a number of concerns about pain management," said Don Dumoulin, President of Empi. "With Hybresis, Empi has taken another step in providing patients with more options for therapeutic relief. Essentially, we've taken the 'pain' out of drug delivery for both patients and the healthcare professionals."

Empi's Hybresis system has regulatory approval through the 510(k) market clearance process of the U.S. Food and Drug Administration (FDA). Prescription by a licensed physician is required.

For more information about Hybresis, please visit http://www.hybresis.com.

About Empi

Empi, a DJO company, is a leading manufacturer and provider of non-invasive medical products for pain management and physical rehabilitation. Headquartered in St. Paul, Minnesota, Empi is committed to delivering positive patient outcomes and providing innovative products specifically designed to meet the needs of the patient, medical professional and payor. More information about Empi and its wide range of pain management products and services can be found on the Company's Web site, http://www.empi.com. More information about DJO can be found on the Company's Web Site at http://www.DJOglobal.com.

Media Contact:

Susan Lombardo

Lois Paul & Partners

781.782.5767

susan_lombardo@lpp.com


'/>"/>
SOURCE Empi
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. MedImmune Resolves FDA Observations Regarding Manufacturing Process for FluMist(R)
2. Whiplash may produce delayed jaw pain
3. Hypnosis Eases Pain of Breast Cancer Surgery
4. Whiplash May Result in Delayed Jaw Pain
5. Figure Skater Peggy Fleming, HealthSaver Says: Take Pains For Back Strains, 2nd Most Common Doctor Complaint
6. Knee Pain May Signal Lung Cancer
7. Consumer Reports Analysis: Drugs for Nerve Pain, Fibromyalgia Effective, But Not Always Best
8. PainCare Receives $14.4 Million in Cash From Completed Sale of South Florida Ambulatory Surgery Centers
9. New study examines brain-gut relationship in those suffering with stomach pain or discomfort
10. Pain patients at risk for sleep apnea
11. Painless Hemorrhoid Treatment Adds Management Punch
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... Little Rock, AR (PRWEB) , ... March 27, 2017 , ... ... the CMSA National Board of Directors on June 30, 2017. CMSA’s membership has ... board. In addition to our current Military Advisory position, a new VA Advisory position ...
(Date:3/27/2017)... ... March 27, 2017 , ... EpiGentek , a ... the recent RNA methylation “gold rush” with their established portfolio of optimized assay ... of N6-methyladenosine, or m6A , RNA methylation has received a new burst ...
(Date:3/27/2017)... ... March 27, 2017 , ... The Anaheim Hills office accelerates and ... Capital has added 10 new sales professionals over the past 6 months and is ... additional new hires over the course of 2017. , “This new office is ...
(Date:3/27/2017)... (PRWEB) , ... March 27, 2017 , ... ... deaths soared 167%,(1) with opioids alone responsible for over 33,000 of the 52,404 ... has sponsored Assembly Bill (AB) 1512, which proposes a tax on prescription opioids ...
(Date:3/25/2017)... ... 2017 , ... Norland at Swissray is pleased to announce the release of the ... ELITE DXA has an active scan window, which is more than double that of existing ... scan area could not undergo an accurate total body bone density or body composition study. ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... , March 27, 2017 Cota ... for value-based precision medicine, today announced the ... Novartis Pharmaceuticals Corporation to help improve clinical ... As part of this agreement, ... collaboration entered into January 2016, teams from ...
(Date:3/27/2017)... , March 27, 2017 Arena Pharmaceuticals, ... focused on developing novel, small molecule drugs across multiple therapeutic ... and Chief Executive Officer, will present a corporate update at ... at 3:40pm ET.  The conference will take place April 4-5, ... New York , NY.  A ...
(Date:3/24/2017)... and PUNE, India , March 24, 2017 ... is estimated to reach $2,614 million by 2022, Globally, registering a CAGR of 5.1% ... the highest revenue, and is projected to dominate the market during the study period. ... ... Market Research Logo ...
Breaking Medicine Technology: